State Street Adds $7M in Arrowhead Pharmaceuticals, Inc. ($ARWR)
State Street raised its holdings in Arrowhead Pharmaceuticals by over 92,000 shares.
Key Points
- State Street boosted its position in Arrowhead Pharmaceuticals by 92,300 shares, bringing its total to 6,496,130 shares worth $526.4 million.
- Arrowhead Pharmaceuticals, trading at $81.04, has a market cap of about $11.4 billion and a 52-week high of $82.48.
- Recent insider transactions include buys by COO Patrick O'Brien and sales by Chief Medical Officer James Hamilton.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
State Street has increased its holdings in Arrowhead Pharmaceuticals, Inc. (NasdaqGS: ARWR), adding 92,300 shares. This brings its total stake to 6,496,130 shares, valued at approximately $526.4 million, according to the latest Form 13F filing with the SEC as of May 15, 2026.
What Changed in State Street's Arrowhead Pharmaceuticals Position
State Street's recent move saw an increase of 92,300 shares in Arrowhead Pharmaceuticals, representing a 1.44% uptick from its previous holding of 6,403,830 shares. The value of the new position is reported at $526.4 million, indicating a continued interest in the biotechnology firm.
Other Institutional Activity in Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals has seen varied activity from other institutional investors as well. BlackRock, Inc. reduced its stake by 3,157,063 shares, holding 18,161,519 shares worth about $1.14 billion. Avoro Capital Advisors LLC increased its position by 74,999 shares, leading to a total of 10,699,999 shares valued at approximately $670.9 million. FMR LLC boosted its holdings by 746,244 shares, ending with 7,266,652 shares valued at $455.6 million. Vanguard Portfolio Management LLC now holds 7,146,136 shares worth about $448.1 million, while Vanguard Capital Management LLC holds 6,032,416 shares valued at $378.2 million.
Arrowhead Pharmaceuticals, Inc. Stock Down 4.2%
Shares of Arrowhead Pharmaceuticals recently traded at $81.04. The company has a market capitalization of around $11.4 billion. Its forward P/E ratio is not meaningful as the company is not currently profitable. Arrowhead has a beta of 1.275, indicating some volatility compared to the market. The stock's 52-week range is between $14.30 and $82.48, with a 50-day moving average of $73.79 and a 200-day moving average of $57.84.
$ARWR stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Arrowhead Pharmaceuticals reported revenue of $622 million, though it saw a revenue decline of 86.4%. The company has a net margin of -48.38% and a return on equity of -42.37%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Arrowhead Pharmaceuticals, Inc.
Recent insider activity includes several transactions. On June 15, 2026, Matthew Gregory Cohen acquired 11,882 shares. On May 12, 2026, Hongbo Lu sold 2,970 shares at $76.88 as part of a planned sale. James Hamilton, the Chief Medical Officer, sold 10,000 shares at $75.00 on April 23, 2026, also as part of a planned sale. Chief Financial Officer Daniel Joseph Apel sold 13,095 shares at $71.35 on April 22, 2026, under a planned sale.
Analysts Set New Price Targets
Several analysts have recently updated their price targets for Arrowhead Pharmaceuticals. On June 17, 2026, Leerink Partners maintained a hold rating with a $72.00 target. Bernstein also maintained a hold rating with a $46.00 target on May 13, 2026. RBC Capital maintained a buy rating with an $87.00 target on May 8, 2026. JP Morgan initiated coverage with a buy rating and an $88.00 target on May 1, 2026. The consensus recommendation is a buy, with an average target price of $88.17 based on 12 analyst opinions.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a biotechnology company based in Pasadena, California. It develops medicines aimed at treating challenging diseases. The company is involved in several clinical trials, including efforts to reduce the production of certain proteins and genes related to various diseases. Arrowhead collaborates with major pharmaceutical companies like GlaxoSmithKline, Takeda, Amgen, and Sarepta Therapeutics. Founded in 2003, the company is led by CEO Dr. Christopher R. Anzalone and employs 711 people.
Bottom Line
State Street's increased stake in Arrowhead Pharmaceuticals reflects ongoing institutional interest in the biotech sector. Investors keep a close eye on such filings to gauge institutional sentiment, though these reports are backward-looking and may not represent current positions. Arrowhead's recent financials and insider activities, along with analyst updates, provide a comprehensive view of the company's current market standing.
Get Arrowhead Pharmaceuticals, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ARWR, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.